Sharon Shui Yee Leung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sharon Shui Yee Leung has a total of 252 co-authors. Here are the top co-authors by number of shared publications:
- Hak-Kim Chan
The University of Sydney
22 shared publications Pengfei Zhang
School of Pharmacy, Faculty of Medicine The Chinese University of Hong Kong Shatin Hong Kong
12 shared publicationsPatricia Tang
Sydney Pharmacy School, University of Sydney
10 shared publicationsPing Zeng
School of Pharmacy, Faculty of Medicine The Chinese University of Hong Kong Shatin Hong Kong
9 shared publicationsYannan Liu
Emergency Medicine Clinical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, PR China
8 shared publications- Brian S. Haynes
The University of Sydney
7 shared publications
Latest Publications
- Open Access
- 21 August 2026
- Published by Wiley in Advanced Science
One‐Step Immobilized Phage Depolymerase Coatings for Catheter‐Related Bloodstream Infections
Catheter‐related bloodstream infection (CRBSI) is an important clinical problem that causes significant mortality and excess economic cost. Recent epidemiological trends indicate a shift in CRBSI pathogens from Gram‐positive to Gram‐negative bacilli, among which Pseudomonas aeruginosa , Klebsiella pneumoniae , and Acinetobacter baumannii predominate due to their strong antibiotic resistance and biofilm‐forming capabilities. Recently, bacteriophage‐encoded depolymerases have emerged as promising antivirulence agents that resensitize bacteria to host immunity by degrading capsular polysaccharides (CPS) and exopolysaccharides (EPS). In this study, we employed a mussel‐inspired polydopamine (PDA) coating technique to immobilize an A. baumannii‐specific depolymerase, DPO71, onto diverse organic, inorganic, and metal substrates, with a maximum surface coverage of ∼0.2 µg/cm 2 . In the presence of human serum, DPO71‐coated surfaces demonstrated potent antibacterial and antibiofilm activities. The coating significantly reduced bacterial burden in an epithelial cell‐bacteria co‐culture system and in ex vivo blood infection models. Moreover, DPO71 coatings demonstrated good robustness, stability, and minimal toxicity toward epithelial cells and Galleria mellonella larvae. Importantly, in a mouse subcutaneous implantation model, the DPO71 coating significantly reduced bacterial load in vivo. Overall, modifying catheter surfaces with depolymerases via a simple PDA coating technique demonstrates great potential in mitigating bacteria‐associated CRBSI.
- 21 August 2026
- Published by Wiley in Advanced Science
Open AccessOne‐Step Immobilized Phage Depolymerase Coatings for Catheter‐Related Bloodstream Infections
Catheter‐related bloodstream infection (CRBSI) is an important clinical problem that causes significant mortality and excess economic cost. Recent epidemiological trends indicate a shift in CRBSI pathogens from Gram‐positive to Gram‐negative bacilli, among which Pseudomonas aeruginosa , Klebsiella pneumoniae , and Acinetobacter baumannii predominate due to their strong antibiotic resistance and biofilm‐forming capabilities. Recently, bacteriophage‐encoded depolymerases have emerged as promising antivirulence agents that resensitize bacteria to host immunity by degrading capsular polysaccharides (CPS) and exopolysaccharides (EPS). In this study, we employed a mussel‐inspired polydopamine (PDA) coating technique to immobilize an A. baumannii‐specific depolymerase, DPO71, onto diverse organic, inorganic, and metal substrates, with a maximum surface coverage of ∼0.2 µg/cm 2 . In the presence of human serum, DPO71‐coated surfaces demonstrated potent antibacterial and antibiofilm activities. The coating significantly reduced bacterial burden in an epithelial cell‐bacteria co‐culture system and in ex vivo blood infection models. Moreover, DPO71 coatings demonstrated good robustness, stability, and minimal toxicity toward epithelial cells and Galleria mellonella larvae. Importantly, in a mouse subcutaneous implantation model, the DPO71 coating significantly reduced bacterial load in vivo. Overall, modifying catheter surfaces with depolymerases via a simple PDA coating technique demonstrates great potential in mitigating bacteria‐associated CRBSI.
- Open Access
- 16 April 2026
- Published by Wiley in Advanced Science
- Vol. 13 (38) , e22326
A Chirality‐Converted Bacteriolytic Dodecapeptide Regulates Vibrio ‐Induced Polymicrobial Infection and Ameliorates Invasion‐Associated Gut Microbiota Disequilibrium
The polymicrobial infections caused by Vibrio species, especially multidrug‐resistant isolates, are posing increasing threats to the health of coastal residents. Herein, a novel dodecapeptide, denoted as D‐zp37 , was designed and synthesized, aiming to combat these notorious pathogens. Experimental results proved that the simple chirality conversion of the parent peptide, zp37 , could significantly boost the antibacterial activity and proteolytic stability. To a specific cephalosporin‐resistant Vibrio alginolyticus , the minimal inhibitory concentration value of D‐zp37 was as low as 0.5 µ m . Beyond the strong bacteriolytic effect against planktonic Vibrio alginolyticus , Vibrio parahaemolyticus and Vibrio vulnificus strains, D‐zp37 was found to restrain the biofilm establishment of Vibrio mixtures via inhibiting the efflux of intracellular polysaccharides. Mechanistic studies hinted that D‐zp37 impeded the electron transport chain, impaired the membrane stress response by downregulating the phage shock protein family, and blocked amino acid biosynthesis in Vibrio cells. Furthermore, three different infection models (shrimp, Galleria mellonella larvae and immunosuppressed mice) collaboratively confirmed the anti‐ Vibrio efficacy of D‐zp37 in vivo. In addition, the intragastric administration of D‐zp37 was found to be beneficial in restoring the imbalanced gut microbiota induced by the polymicrobial Vibrio invasion. In summary, this work investigated the antibacterial mechanisms and in vivo efficacy of a novel peptide lead compound, proposing a new therapeutic against Vibrio infections.
- 16 April 2026
- Published by Wiley in Advanced Science
- Vol. 13 (38) , e22326
Open AccessA Chirality‐Converted Bacteriolytic Dodecapeptide Regulates Vibrio ‐Induced Polymicrobial Infection and Ameliorates Invasion‐Associated Gut Microbiota Disequilibrium
The polymicrobial infections caused by Vibrio species, especially multidrug‐resistant isolates, are posing increasing threats to the health of coastal residents. Herein, a novel dodecapeptide, denoted as D‐zp37 , was designed and synthesized, aiming to combat these notorious pathogens. Experimental results proved that the simple chirality conversion of the parent peptide, zp37 , could significantly boost the antibacterial activity and proteolytic stability. To a specific cephalosporin‐resistant Vibrio alginolyticus , the minimal inhibitory concentration value of D‐zp37 was as low as 0.5 µ m . Beyond the strong bacteriolytic effect against planktonic Vibrio alginolyticus , Vibrio parahaemolyticus and Vibrio vulnificus strains, D‐zp37 was found to restrain the biofilm establishment of Vibrio mixtures via inhibiting the efflux of intracellular polysaccharides. Mechanistic studies hinted that D‐zp37 impeded the electron transport chain, impaired the membrane stress response by downregulating the phage shock protein family, and blocked amino acid biosynthesis in Vibrio cells. Furthermore, three different infection models (shrimp, Galleria mellonella larvae and immunosuppressed mice) collaboratively confirmed the anti‐ Vibrio efficacy of D‐zp37 in vivo. In addition, the intragastric administration of D‐zp37 was found to be beneficial in restoring the imbalanced gut microbiota induced by the polymicrobial Vibrio invasion. In summary, this work investigated the antibacterial mechanisms and in vivo efficacy of a novel peptide lead compound, proposing a new therapeutic against Vibrio infections.
- 24 March 2026
- Published by Elsevier in Microbial Pathogenesis
- Vol. 215, 108463
How amphiphilic attributes of cationic dodecapeptides affect their bioactivity against gram-negative pathogens
- 24 March 2026
- Published by Elsevier in Microbial Pathogenesis
- Vol. 215, 108463
How amphiphilic attributes of cationic dodecapeptides affect their bioactivity against gram-negative pathogens
- Open Access
- 6 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (10) , eadw0891
A worm-like nucleic acid nanostructure for gene delivery and endosomal escape via ClC3 ion exchanger
Nanoparticle-based gene delivery can enable therapeutic applications with lower cytotoxicity than viral vectors, but its efficacy is often hampered by endosomal entrapment. We present a nucleic acid nanotechnology approach to circumvent this delivery bottleneck by adsorbing therapeutic nucleic acids (DNA, small interfering RNA, microRNA, or messenger RNA) to a gold-polydopamine nanoworm template, thereby assembling a three-dimensional worm-like nucleic acid nanostructure. Devoid of cationic groups, lipids, or mechanical stimuli, this nanostructure naturally activates the chloride voltage-gated channel 3 (ClC3) ion exchanger in endosomes given its worm-like shape; in turn, ClC3 mediates endosomal H + and Cl − accumulation and eventual membrane rupture for cytosolic release, contributing to robust endosomal escape with a correlation coefficient <0.2 between the nanostructure and endosomes. We showcase in vitro gene regulation for primary macrophage polarization and mesenchymal stromal cell differentiation, ex vivo programmable mesenchymal stromal cell–based therapy for kidney fibrosis, and in vivo hepatocyte delivery for treating liver injury. Our versatile nucleic acid nanostructure will empower safe and effective gene therapies.
- 6 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (10) , eadw0891
Open AccessA worm-like nucleic acid nanostructure for gene delivery and endosomal escape via ClC3 ion exchanger
Nanoparticle-based gene delivery can enable therapeutic applications with lower cytotoxicity than viral vectors, but its efficacy is often hampered by endosomal entrapment. We present a nucleic acid nanotechnology approach to circumvent this delivery bottleneck by adsorbing therapeutic nucleic acids (DNA, small interfering RNA, microRNA, or messenger RNA) to a gold-polydopamine nanoworm template, thereby assembling a three-dimensional worm-like nucleic acid nanostructure. Devoid of cationic groups, lipids, or mechanical stimuli, this nanostructure naturally activates the chloride voltage-gated channel 3 (ClC3) ion exchanger in endosomes given its worm-like shape; in turn, ClC3 mediates endosomal H + and Cl − accumulation and eventual membrane rupture for cytosolic release, contributing to robust endosomal escape with a correlation coefficient <0.2 between the nanostructure and endosomes. We showcase in vitro gene regulation for primary macrophage polarization and mesenchymal stromal cell differentiation, ex vivo programmable mesenchymal stromal cell–based therapy for kidney fibrosis, and in vivo hepatocyte delivery for treating liver injury. Our versatile nucleic acid nanostructure will empower safe and effective gene therapies.
- Open Access
- 2 March 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (3) , 318
Targeting Intratumoral Bacteria for Enhanced Tumor Suppression with Nano-Based Therapeutics: A Scoping Review
Background: Increasing evidence identifies intratumoral bacteria as key modulators of tumor progression, chemoresistance, and immunosuppression, presenting major obstacles to conventional cancer therapies. Recent advances in nanotechnology have enabled new strategies for selective targeting bacteria within the tumor microenvironment, potentially improving anticancer efficacy. Methods: A scoping review was conducted to outline the current landscape of nano-based therapeutic approaches aimed at the simultaneous elimination of intratumoral bacteria and cancer. Preclinical research publications involving in vivo antitumor efficacy evaluations were retrieved from three databases, Web of Science, PubMed, and Scopus, using the key words “(kill* OR eradicate* OR eliminate*) AND intratumoral AND (bacteria OR infection)”. Key information from the eligible studies was extracted and analyzed. Results: The diversity of bacterial species, cancer models, and evaluation methodologies employed in these preclinical studies were summarized, followed by critical examination of the design principles, therapeutic outcomes, and translational challenges of various nanomedicine platforms, including passive and active targeting drug delivery systems, phototherapy, phage therapy, and emerging modalities. Nano-based therapeutics functionalized with both antibacterial and anticancer properties were shown to effectively overcome bacteria-induced treatment resistance. Conclusions: Targeting intratumoral bacteria may significantly enhance the efficacy of existing treatments and contribute to the evolution of precision oncology. The insights gained from this review are expected to guide future systematic reviews and inform research directions in the development of dual-functional nanomedicines for cancer therapy.
- 2 March 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (3) , 318
Open AccessTargeting Intratumoral Bacteria for Enhanced Tumor Suppression with Nano-Based Therapeutics: A Scoping Review
Background: Increasing evidence identifies intratumoral bacteria as key modulators of tumor progression, chemoresistance, and immunosuppression, presenting major obstacles to conventional cancer therapies. Recent advances in nanotechnology have enabled new strategies for selective targeting bacteria within the tumor microenvironment, potentially improving anticancer efficacy. Methods: A scoping review was conducted to outline the current landscape of nano-based therapeutic approaches aimed at the simultaneous elimination of intratumoral bacteria and cancer. Preclinical research publications involving in vivo antitumor efficacy evaluations were retrieved from three databases, Web of Science, PubMed, and Scopus, using the key words “(kill* OR eradicate* OR eliminate*) AND intratumoral AND (bacteria OR infection)”. Key information from the eligible studies was extracted and analyzed. Results: The diversity of bacterial species, cancer models, and evaluation methodologies employed in these preclinical studies were summarized, followed by critical examination of the design principles, therapeutic outcomes, and translational challenges of various nanomedicine platforms, including passive and active targeting drug delivery systems, phototherapy, phage therapy, and emerging modalities. Nano-based therapeutics functionalized with both antibacterial and anticancer properties were shown to effectively overcome bacteria-induced treatment resistance. Conclusions: Targeting intratumoral bacteria may significantly enhance the efficacy of existing treatments and contribute to the evolution of precision oncology. The insights gained from this review are expected to guide future systematic reviews and inform research directions in the development of dual-functional nanomedicines for cancer therapy.
- Open Access
- 13 February 2026
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 67 (5) , 107745
Treatment sequences of a phage and colistin combination trigger different evolution pathways of a multidrug-resistant Acinetobacter baumannii yielding distinct treatment outcomes
- 13 February 2026
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 67 (5) , 107745
Open AccessTreatment sequences of a phage and colistin combination trigger different evolution pathways of a multidrug-resistant Acinetobacter baumannii yielding distinct treatment outcomes
- Open Access
- 28 July 2025
- Published by Elsevier in Pharmacological Research
- Vol. 221, 107888
Therapeutical peptides – Rapidly developing pharmaceutical landscape
- 28 July 2025
- Published by Elsevier in Pharmacological Research
- Vol. 221, 107888
Open AccessTherapeutical peptides – Rapidly developing pharmaceutical landscape
- Open Access
The Cyclic Peptide Cyclo-zp80r Controls Salmonella enterica and Listeria monocytogenes Replication in Non-Concentrated (NFC) Orange Juice: Antibacterial Effects and Mechanisms of Action
The market for non-concentrated (NFC) orange juice is increasing rapidly due to consumer demand for nutrients and flavor. However, it encounters challenges in microbial safety, particularly from Salmonella enterica and Listeria monocytogenes. This study aimed to exploit a bio-preservative for NFC orange juice. Results showed that the cyclic peptide cyclo-zp80r had good antibacterial activity, with minimum inhibitory concentration values of 2–8 μM against S. enterica and L. monocytogenes. It exhibited bactericidal action against S. enterica and bacteriostatic action against L. monocytogenes at a concentration of 128 μM. This study explored the effect of cyclo-zp80r on the pathogenicity of S. enterica and L. monocytogenes. The mortality rate of Galleria mellonella exposed to these pathogens in NFC orange juice decreased from 100% to 60% after cyclo-zp80r treatment, surpassing the effectiveness of nisin. Cyclo-zp80r exhibited depolarization effects on S. enterica and L. monocytogenes. It increased outer membrane permeability and damaged the membrane structure of S. enterica. Cyclo-zp80r also caused distinct morphological changes, mainly cell collapse in S. enterica and localized bubble-like protrusions in L. monocytogenes. It induced reactive oxygen species production and DNA binding. The species diversity and abundance in NFC orange juice were also reduced by cyclo-zp80r, particularly in the genera Pantoea, Aeromonas, Pseudomonas, and Erwinia. Additionally, cyclo-zp80r exhibited excellent stability at high temperature (121 °C, 5 min) and in fresh orange juice. These results suggest that cyclo-zp80r could be developed as an effective food bio-preservative.
Open AccessThe Cyclic Peptide Cyclo-zp80r Controls Salmonella enterica and Listeria monocytogenes Replication in Non-Concentrated (NFC) Orange Juice: Antibacterial Effects and Mechanisms of Action
The market for non-concentrated (NFC) orange juice is increasing rapidly due to consumer demand for nutrients and flavor. However, it encounters challenges in microbial safety, particularly from Salmonella enterica and Listeria monocytogenes. This study aimed to exploit a bio-preservative for NFC orange juice. Results showed that the cyclic peptide cyclo-zp80r had good antibacterial activity, with minimum inhibitory concentration values of 2–8 μM against S. enterica and L. monocytogenes. It exhibited bactericidal action against S. enterica and bacteriostatic action against L. monocytogenes at a concentration of 128 μM. This study explored the effect of cyclo-zp80r on the pathogenicity of S. enterica and L. monocytogenes. The mortality rate of Galleria mellonella exposed to these pathogens in NFC orange juice decreased from 100% to 60% after cyclo-zp80r treatment, surpassing the effectiveness of nisin. Cyclo-zp80r exhibited depolarization effects on S. enterica and L. monocytogenes. It increased outer membrane permeability and damaged the membrane structure of S. enterica. Cyclo-zp80r also caused distinct morphological changes, mainly cell collapse in S. enterica and localized bubble-like protrusions in L. monocytogenes. It induced reactive oxygen species production and DNA binding. The species diversity and abundance in NFC orange juice were also reduced by cyclo-zp80r, particularly in the genera Pantoea, Aeromonas, Pseudomonas, and Erwinia. Additionally, cyclo-zp80r exhibited excellent stability at high temperature (121 °C, 5 min) and in fresh orange juice. These results suggest that cyclo-zp80r could be developed as an effective food bio-preservative.
- 11 June 2025
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 681, 125842
Storage stability prediction of spray dried Anti-Acinetobacter baumannii phage and phage cocktail powders
- 11 June 2025
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 681, 125842
Storage stability prediction of spray dried Anti-Acinetobacter baumannii phage and phage cocktail powders
- Open Access
- 15 May 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (16) , e2500659
Fabrication of a Lipopolysaccharide‐Targeting Peptide‐Based Colloid for Alleviating Carbapenem‐Resistant Enterobacteriaceae‐Induced Cutaneous Infection
Carbapenem‐resistant Enterobacteriaceae (CRE) becomes a growing threat to human health. Many clinical isolates have shown strong resistance to commonly used antibacterial agents. Inspired by cationic amphiphiles with tandem‐repeat sequence, two novel peptides termed IW (IWRRIWRRIWRRIWRR‐NH2) and WI (WIRRWIRRWIRRWIRR‐NH2) are designed, synthesized, and investigated in this study. Both exhibited favorable antibacterial activity against “superbugs” at micromole level, surpassing conventional antibiotics, like meropenem and imipenem. Adopting the analytic strategies of molecular dynamics simulation in combination with experimental verification, lipopolysaccharide (LPS) is proposed as a potential target for IW with a calculated dissociation constant of 886 ± 879 nM. Though deadly to infamous bacteria, IW demonstrated negligible toxicity to Galleria mellonella (GM) larvae at 500 mg kg−1. For better administration, IW was formulated with a commercial pharmaceutical excipient poloxamer 407 (P407) to fabricate an antibacterial colloid. This material was verified to effectively reduce the bacterial burden of Escherichia coli‐infected skin in a mouse model by ≈1.5 log compared with the P407‐treated group. Overall, this work expanded the potential arsenal against carbapenem‐resistant strains by introducing a new engineered molecule delivered using a cheap, concise formulation strategy accordingly.
- 15 May 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (16) , e2500659
Open AccessFabrication of a Lipopolysaccharide‐Targeting Peptide‐Based Colloid for Alleviating Carbapenem‐Resistant Enterobacteriaceae‐Induced Cutaneous Infection
Carbapenem‐resistant Enterobacteriaceae (CRE) becomes a growing threat to human health. Many clinical isolates have shown strong resistance to commonly used antibacterial agents. Inspired by cationic amphiphiles with tandem‐repeat sequence, two novel peptides termed IW (IWRRIWRRIWRRIWRR‐NH2) and WI (WIRRWIRRWIRRWIRR‐NH2) are designed, synthesized, and investigated in this study. Both exhibited favorable antibacterial activity against “superbugs” at micromole level, surpassing conventional antibiotics, like meropenem and imipenem. Adopting the analytic strategies of molecular dynamics simulation in combination with experimental verification, lipopolysaccharide (LPS) is proposed as a potential target for IW with a calculated dissociation constant of 886 ± 879 nM. Though deadly to infamous bacteria, IW demonstrated negligible toxicity to Galleria mellonella (GM) larvae at 500 mg kg−1. For better administration, IW was formulated with a commercial pharmaceutical excipient poloxamer 407 (P407) to fabricate an antibacterial colloid. This material was verified to effectively reduce the bacterial burden of Escherichia coli‐infected skin in a mouse model by ≈1.5 log compared with the P407‐treated group. Overall, this work expanded the potential arsenal against carbapenem‐resistant strains by introducing a new engineered molecule delivered using a cheap, concise formulation strategy accordingly.